Bay Area biotech hauls in $62M to pay the freight on ear­ly-stage CD33/CD3 T cell en­gager

South San Fran­cis­co-based Am­phive­na Ther­a­peu­tics has hauled in $62 mil­lion in cash as the R&D team slogs through ear­ly-stage de­vel­op­ment of their bis­pe­cif­ic CD33 and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER